How to Cite
Abstract
The therapeutic management of rheumatic disorders has faced new challenges in the post-COVID period, as conventional treatment approaches often prove insufficient in controlling persistent immune activation, vascular impairment, and accelerated connective tissue remodeling. SARS-CoV-2 infection induces prolonged disturbances in cytokine regulation, endothelial homeostasis, and metabolic balance, all of which substantially influence disease activity, progression, and responsiveness to therapy in ankylosing spondylitis, rheumatoid arthritis, reactive arthritis, osteoarthritis, allergic vasculitis, systemic sclerosis, and in patients with concomitant chronic ischemic heart disease.
References
This work is licensed under a Creative Commons Attribution 4.0 International License.